PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
PRTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
PRTA had negative earnings in the past year.
In the past year PRTA has reported a negative cash flow from operations.
PRTA had negative earnings in 4 of the past 5 years.
PRTA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PRTA has a Return On Assets of -21.12%. This is amongst the best in the industry. PRTA outperforms 80.85% of its industry peers.
PRTA's Return On Equity of -26.20% is amongst the best of the industry. PRTA outperforms 82.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.12% | ||
| ROE | -26.2% | ||
| ROIC | N/A |
ROA(3y)-8.51%
ROA(5y)-15.49%
ROE(3y)-10.2%
ROE(5y)-23.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTA has been increased compared to 1 year ago.
PRTA has more shares outstanding than it did 5 years ago.
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PRTA has an Altman-Z score of 3.51. This indicates that PRTA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PRTA (3.51) is better than 76.92% of its industry peers.
There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.51 |
ROIC/WACCN/A
WACC7.42%
2.3 Liquidity
A Current Ratio of 11.24 indicates that PRTA has no problem at all paying its short term obligations.
PRTA has a Current ratio of 11.24. This is amongst the best in the industry. PRTA outperforms 83.59% of its industry peers.
PRTA has a Quick Ratio of 11.24. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PRTA (11.24) is better than 83.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.24 | ||
| Quick Ratio | 11.24 |
3. Growth
3.1 Past
The earnings per share for PRTA have decreased strongly by -11.55% in the last year.
The Revenue has grown by 69.60% in the past year. This is a very strong growth!
The Revenue has been growing by 146.70% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-11.55%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1150%
Revenue 1Y (TTM)69.6%
Revenue growth 3Y366.5%
Revenue growth 5Y146.7%
Revenue growth Q2Q-99.37%
3.2 Future
The Earnings Per Share is expected to grow by 27.97% on average over the next years. This is a very strong growth
PRTA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.65% yearly.
EPS Next Y-76.76%
EPS Next 2Y-22.53%
EPS Next 3Y1.48%
EPS Next 5Y27.97%
Revenue Next Year-86.61%
Revenue Next 2Y3.62%
Revenue Next 3Y30.6%
Revenue Next 5Y56.65%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.53%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
No dividends for PRTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROTHENA CORP PLC
NASDAQ:PRTA (4/15/2024, 7:26:25 PM)
After market: 21.99 0 (0%)21.99
-0.25 (-1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.12% | ||
| ROE | -26.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.24 | ||
| Quick Ratio | 11.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-11.55%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-76.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)69.6%
Revenue growth 3Y366.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y